Dr Reddys Laboratories Ltd (DRREDDY)

Dr. Reddy's Launches Generic Antibiotic in US Market - 03 May, 2024

Dr. Reddy's Laboratories has launched Doxycycline Capsules, 40 mg, a broad-spectrum antibiotic used to treat bacterial infections and parasites, in the US market as a therapeutic generic equivalent of ORACEA capsules.

Indian Pharma Companies Expected to Benefit from Patent Cliff and Short Supply of Key Drugs - 02 May, 2024

Unmesh Sharma, Head of Institutional Equities at HDFC Securities, expects Indian pharma companies including Dr Reddys Labs, Sun Pharma, Cipla, and Aurobindo Pharma to benefit from the patent cliff and short supply of key drugs due to the closure of facilities of several manufacturers. This creates incremental revenue opportunities for Indian players.

Dr. Reddys Forms JV with Nestle India for Nutritional Health Solutions - 25 Apr, 2024

Dr. Reddys Laboratories has formed a joint venture with Nestle India to widen the reach of Nestle's nutritional solutions in India by leveraging Dr. Reddys' retail and distribution network. The joint venture will focus on complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness, women's health, and child nutrition.

Dr. Reddy's Recalls Medication in the US - 24 Apr, 2024

Dr. Reddy's Laboratories has issued a voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg in the US due to discolouration and decreased potency, which could lead to permanent neurocognitive deficits and developmental delays. The shares were up by 0.31% at ₹5,972.30 on the BSE.

Dr. Reddys Launches Integrated Care Plan for IBS - 22 Apr, 2024

Dr. Reddys Laboratories has launched DailyBloom IBS, the first integrated care plan for irritable bowel syndrome in India.

Dr. Reddys Launches Integrated Care Plan for IBS - 19 Apr, 2024

Dr. Reddys Laboratories has launched DailyBloom IBS, an integrated care plan for Irritable Bowel Syndrome (IBS), which includes diet management and psychological and physical wellness support. The programme is enabled by a mobile application developed in-house.

Dr. Reddy's Laboratories Ltd has a lower P/E ratio than the market average - 18 Apr, 2024

Dr. Reddy's Laboratories Ltd has been performing well with superior earnings growth compared to most other companies, but investors think this strong earnings performance might be less impressive moving forward. The company grew EPS by 43% last year and is estimated to generate growth of 2.7% per annum in the next three years as forecasted by analysts. However, unless these conditions improve, they will continue to form a barrier for the share price around current levels.

Dr Reddys Launches Migraine Management Device in Europe - 12 Apr, 2024

Dr Reddys Laboratories has launched Nerivio, a drug-free migraine management device in Germany via its subsidiary Betapharm. The wearable device is approved by the USFDA and CE-mark certified in Europe. Following its European debut, it will be launched in South Africa later this month, with subsequent introductions in Spain and the UK.

Dr. Reddy's Launches Migraine Management Wearable Device in Europe - 11 Apr, 2024

Dr. Reddy's Laboratories has entered the digital therapeutics market in Europe with the launch of Nerivio, a non-invasive migraine management wearable device approved by the USFDA and CE-mark certified in Europe. The company plans to launch the product in South Africa later this month and subsequently in Spain and the UK.

Dr. Reddy's Launches Migraine Management Device in Europe - 10 Apr, 2024

Dr. Reddy's Laboratories has launched its non-invasive migraine management wearable device, Nerivio, in Germany through its subsidiary Betapharm. The launch marks the company's entry into digital therapeutics in Europe and is approved by the USFDA and CE-mark certified.

Dr. Reddy's Labs Expected to Post Strong Q4 Results - 09 Apr, 2024

Analysts forecast a 14-15% YoY revenue growth for Indian pharma companies in Q4FY24, with MOSL predicting strong results for Dr. Reddy's Labs due to robust domestic business and US sales growth.

Sanofi Forms Strategic Alliances with Indian Pharma Firms - 07 Apr, 2024

Sanofi has partnered with Cipla, Dr. Reddys Laboratories, and Emcure to expand its market reach in India. The collaborations aim to maximize the impact of Sanofi's existing products.

Dr. Reddy's Partners with Bayer for Vericiguat Distribution - 06 Apr, 2024

Dr. Reddy's Laboratories has entered into a partnership agreement with Bayer to market and distribute Vericiguat, a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event, in India under the brand name Gantra.

Dr Reddys Partners with Bayer for Heart Failure Medication - 05 Apr, 2024

Dr Reddys Laboratories has partnered with Bayer to introduce a second brand of Vericiguat, a medication for chronic heart failure, to the Indian market. The partnership will expand access to this treatment for a wider range of patients in India.